本文選題：TPP + 生物制品數(shù)據(jù)保護(hù)��； 參考：《上海醫(yī)藥》2016年17期

【摘要】：本文從《跨太平洋伙伴關(guān)系協(xié)議》(TPP)生物制品數(shù)據(jù)保護(hù)條款出發(fā),在剖析條款要點與制度效應(yīng)基礎(chǔ)上,根據(jù)產(chǎn)業(yè)發(fā)展水平探究我國生物制品數(shù)據(jù)保護(hù)政策定位問題。研究發(fā)現(xiàn),現(xiàn)階段我國創(chuàng)新投入水平和居民支付能力與生物制品數(shù)據(jù)保護(hù)制度并不匹配,實施該制度的負(fù)效應(yīng)將大正效應(yīng)。建議我國在完善產(chǎn)業(yè)配套制度、促進(jìn)產(chǎn)業(yè)轉(zhuǎn)型升級的同時,審時度勢,謹(jǐn)慎分析利弊,并設(shè)計相應(yīng)談判策略預(yù)案。
[Abstract]:In this paper, based on the data protection provisions of TPP- (Trans-Pacific Partnership Agreement), based on the analysis of the key points of the terms and the institutional effects, this paper probes into the policy orientation of the data protection of biological products in China according to the level of industrial development. It is found that the level of innovation input and residents' ability to pay in China do not match with the data protection system of biological products at the present stage, and the negative effects of the system will be positive. It is suggested that our country should, while perfecting the supporting system of industry and promoting industrial transformation and upgrading, review the situation, carefully analyze the pros and cons, and design the corresponding negotiation strategy plan.
【作者單位】： 中國藥科大學(xué);
【基金】：國家社會科學(xué)基金《TRIPS框架下中國藥品試驗數(shù)據(jù)保護(hù)制度研究》(13BFX120) 國家食品藥品監(jiān)督管理總局委托項目《生物制品數(shù)據(jù)保護(hù)策略研究》
【分類號】：R951
，

本文編號：1995750